PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 20, 2018-- GlycoMimetics, Inc. (Nasdaq:GLYC), a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock
View HTML
Toggle Summary GlycoMimetics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 19, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its
View HTML
Toggle Summary GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
Data supports expanding use of GMI-1271 in patients with AML who are unfit for chemotherapy GMI-1359 shows potential in treating osteosarcoma and other cancers ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 14, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical research suggesting
View HTML
Toggle Summary GlycoMimetics to Present at Four Investor Conferences This Month
ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 7, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including: 30 th Annual ROTH Conference March 11 – 14, 2018, The Ritz Carlton, Dana Point, CA CFO Brian Hahn will present
View HTML
Toggle Summary GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results
In an oral presentation of data from its Phase 1/2 AML trial of GMI-1271 at the American Society of Hematology Annual Meeting (ASH), GlycoMimetics reported: Improvements in median overall survival compared to historical matched controls for two AML patient populations Improvements in other clinical
View HTML
Toggle Summary GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML
Primary endpoint for single pivotal clinical trial will be overall survival Top-line data expected Q4 2020 Multiple clinical readouts planned starting year-end 2018 and through 2019 and 2020 Details on Phase 3 development plan tomorrow as part of YE financial results conference call: scheduled for
View HTML
Toggle Summary GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018
Discussion to focus on Phase 3 development plans for GMI-1271 in AML ROCKVILLE, Md. --(BUSINESS WIRE)--Feb. 27, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to provide an update on development plans for GMI-1271 in acute myeloid leukemia
View HTML
Toggle Summary GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy
Trial in patients with AML and “unfit” for chemotherapy, as well as those with Myelodysplastic Syndrome ( MDS), expands potential indications for GMI-1271 and complements planned GlycoMimetics -sponsored registration trial in patients with relapsed/refractory AML Company on track to disclose
View HTML
Toggle Summary GlycoMimetics Added To NASDAQ Biotechnology Index
ROCKVILLE, Md. --(BUSINESS WIRE)--Dec. 15, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will be included in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017 .
View HTML
Toggle Summary GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271
Clinical outcomes, including durability of remission and median overall survival, in high-risk patients plus safety and tolerability data presented in oral presentation at American Society of Hematology Annual Meeting and Expo Second oral presentation highlights underlying, differentiated mechanism
View HTML